Stürzl Roman, Gerken Michael, Bruns Christiane, Klinkhammer-Schalke Monika, Pauer Armin, Piso Pompiliu
Tumorzentrum, Institut für Qualitätssicherung und Versorgungsforschung, Universität Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.
Bayrisches Krebsregister, Regionalzentrum Regensburg, Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Regensburg, Deutschland.
Chirurgie (Heidelb). 2022 Nov;93(11):1072-1081. doi: 10.1007/s00104-022-01703-x. Epub 2022 Aug 20.
The incidence of adenocarcinoma of the esophagogastric junction (AEG) has significantly increased. However, the best surgical treatment for AEG type II is still the subject of current research. The goal of this retrospective cohort study is to compare survival and recurrence rates in patients, who underwent either thoracoabdominal esophagectomy (TAE) or transhiatal extended gastrectomy (TEG).
The study is based on a cohort of 272 patients diagnosed with AEG type II between 2002 and 2020, recorded by a population-based clinical cancer registry. Of the included patients 63 underwent TAE and 209 TEG. In order to compare overall survival, recurrence rates, and recurrence free survival, we applied the Kaplan-Meier method, univariable and multivariable Cox regression.
Our analysis showed no statistically significant difference concerning overall survival (p = 0.333). However a tendency towards higher survival rates after TAE for the period from 2016-2020 (p = 0,058) is possible. In contrast a significant difference concerning higher cumulative recurrence rates after TAE was found after Kaplan-Meier analysis (p = 0.049). This trend was not observed for the time after 2016 (p = 0.993), in which over 50% of TAE were performed. No differences were found regarding recurrence-free survival (p = 0.772).
Our findings in a rather small cohort are concordant with most studies showing no differences or a trend towards better survival after TAE. Other studies found no significant difference regarding recurrence-free survival as well. In conclusion, no significant differences were found between TEG and TAE in surgical treatment of AEG type II.
食管胃交界腺癌(AEG)的发病率显著上升。然而,II型AEG的最佳手术治疗方法仍是当前研究的课题。这项回顾性队列研究的目的是比较接受胸腹联合食管切除术(TAE)或经裂孔扩大胃切除术(TEG)的患者的生存率和复发率。
该研究基于一个队列,纳入了2002年至2020年间由基于人群的临床癌症登记处记录的272例诊断为II型AEG的患者。纳入的患者中,63例行TAE,209例行TEG。为了比较总生存率、复发率和无复发生存率,我们应用了Kaplan-Meier法、单变量和多变量Cox回归分析。
我们的分析显示,总生存率无统计学显著差异(p = 0.333)。然而,2016年至2020年期间TAE术后生存率有升高趋势(p = 0.058)。相比之下,Kaplan-Meier分析发现TAE术后累积复发率有显著差异(p = 0.049)。2016年后未观察到这种趋势(p = 0.993),在此期间超过50%的TAE手术得以实施。无复发生存率方面未发现差异(p = 0.772)。
我们在一个相对较小队列中的研究结果与大多数研究一致,这些研究表明TAE术后无差异或有生存改善趋势。其他研究在无复发生存率方面也未发现显著差异。总之,在II型AEG的手术治疗中,TEG和TAE之间未发现显著差异。